Tarsus Pharmaceuticals announces Q3 earnings per share of 30 cents, below consensus estimate of 33 cents.
Reports Q3 revenue $118.7M, consensus $115.22M. "Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we're having on patients," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "We've established a new category in eye care, and XDEMVY is now one of the best-selling prescription eye drops. Simultaneously, we are expanding our pipeline with more category-creating programs like ocular rosacea - another widespread condition with significant unmet need - that position Tarsus for sustained, long-term growth. With each new milestone, we are deepening our impact and shaping the future of eye care."
